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Introduction 
The prevalence of  type 2 diabetes shows a significant rise world 
wide [1]. Diabetic Retinopathy (DR) and Nephropathy (DN) are 
the most common microvas-cular complications of  diabetes [2]. 
They share com-mon pathogenic mechanisms even though com-
mon pathways of  capillary damage may lead to different struc-
ture and functions of  the organs involved. High prevalence of  
proteinuria in patients with prolifera-tive retinopathy has been 
reported earlier [3] and some studies reported that DR is more 
severe in patients with severe DN and those with advanced DN 
have far more lesions of  DR than those without DN [2,4]. These 
studies lay evidence that DR and DN coexist and there is a close 
relationship between the develop-ment and progression of  these 
two complications.
There are few similarities in the coexistence of  DR and DN be-
ing both as microvascular disease and mi-croscopically both have 
capillary basement membrane thickening. However, capillary clo-
sure is apparent in the retina and kidney after sufficient exposure 
to dis-ease with duration. The pathophysiology of  DN and DR 
is more or less similar, which commences with in-crease in vascu-
lar permeability. The selective increase in permeability to albumin 
in early DN is caused by loss of  polarity across the glomerular 
basement mem-brane [5] and the disease mechanism in the eye 
is prob-ably a breakdown of  tight junctions between cells. The 
onset of  proteinuria and proliferative retinopathy are both related 
to previous poor glycemic control, dura-tion of  diabetes and hy-
pertension [6-8].
It has been suggested that 25-50% of  type 2 diabetic patients may 
have kidney alterations [9]. From the re-cent studies, it is evident 
that the presence of  retinopa-thy itself  may reveal patients at risk 
for nephropathy [10-12]. In a cross sectional study of  patients 
with type 1 and type 2 diabetes to determine the predictive value 
of  DR, univariate analysis indicated that patients with DR were 
5.68, 13.39 and 3.51 times as likely to have DN compared with 
those without DR in the whole study population and in type 1 and 
type 2 diabetes re-spectively [10].
The association between DR and DN has been dem-onstrated in 
other populations. However, there is lack of  evidence that deter-
mine the association of  retinal-renal complications among sub-
jects with type 2 diabe-tes in India. Hence the aim was to evaluate 
the impact of  retinopathy as assessed by Fundus Photography 
and Fundus Fluorescein Angiography (FFA) on the rate of  pro-
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Aim: The aim of  this study was to determine the relationship between retinal-renal complications among type 2 diabetic subjects in 
India.
Subjects and Methods: A total of  502 subjects with type 2 diabetes who underwent Fundus Photography and Fundus Fluorescein 
Angiography (FFA) for diabetic retinopathy (DR) and 24hr urinary creatinine clearance (Crcl) test for diabetic nephropathy (DN) on 
the same day were included in this analysis. They were divided into groups based on the severity of  retinopathy and Crcl values. Out 
of  502 subjects, 272 subjects had subsequent follow-up details spanning 22 months. Anthropometric, haemodynamic and biochemical 
details at baseline and follow-up and mortality details were recorded.
Results: The mean Crcl values decreased significantly with increasing severity of  DR (p<0.001). The percentage of  subjects with 
non-proliferative diabetic retinopathy also decreased with decreasing Crcl. In the follow-up data, severity of  DR increased compared 
to baseline as per stages of  Crcl. There was a decline in survival when both the complications are present. Number of  subjects who 
died was high at severe stages of  these complications. Crcl was significantly associated with declining status of  both the complications.
Conclusions: The degree of  diabetic retinopathy and severity of  diabetic nephropathy showed significant asso-ciation among type2 
diabetic subjects
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gression of  nephropathy as assessed by creatinine clearance (Crcl) 
in 24hr urine collection. We also aimed to evaluate the associated 
risk factors and its outcome in the coexistence of  these two com-
plications.
Materials and Methods
Subjects with type 2 diabetes who underwent retinal and renal 
examination on the same day from June 2006 to June 2007 in a 
tertiary care hospital in India were included in this study. All the 
subjects underwent Fun-dus Photography and FFA for DR and 
24 hour urinary Crcl test for DN. Those who had presence of  
DR (any grade) attributable to type 2 diabetes and with persis-tent 
proteinuria were included and subjects with type 1 diabetes, gesta-
tional diabetes and subjects with incom-plete laboratory data were 
excluded from this analysis. A total of  502 (M:F 351:151) subjects 
with mean age of  55.8 years and mean duration of  diabetes of  
13.8 years were selected for this analysis. Out of  502 sub-jects, 
272 (M:F 191:81) subjects who had subsequent follow-up details 
of  both the complications spanning a median follow-up period 
of  22 months were further analysed for their outcome. All the 
follow-up bio-chemical, anthropometric and haemodynamic de-
tails were obtained from the medical records of  the sub-jects. All 
the subjects were known diabetic patients and were on treatment 
with oral hypoglycemic agents and known hypertensives were on 
antihypertensive medi-cation. The study was approved by the In-
stitutional Ethics committee.
Retinal examination was performed in all the subjects by a trained 
ophthalmologist. Fundus Photography was taken to document 
DR followed by FFA to con-firm findings, to look for macular 
ischaemia and to rule out subtle neovascularization. DR was clas-
sified based on International Clinical Diabetic Retinopathy and 
Diabetic Macular Edema Disease Severity Scales [13].
This international clinical classification system is based on an 
evidence-based approach of  ETDRS and WESDR studies. Retin-
opathy was classified as non-prolifer-ative (microaneurysms, in-
tra-retinal hemorrhages, hard exudates without new vessels) or 
proliferative (newly formed blood vessels and/or growth of  fi-
brous tissue into the vitreous cavity or scars of  photocoagulation). 
Subjects were divided into groups based on the sever-ity of  DR 
[Group1 had Non-Proliferative Diabetic Retinopathy (NPDR) 
(n=231), group2 had clinically significant macular edema (NPDR 
with maculopathy) (n=231) and group3 subjects had Proliferative 
Dia-betic Retinopathy (PDR) (n=40)]. They were further divid-
ed into groups based on the Crcl values as per KDOQI guide-
lines from stage 1 to stage 4. Stage1 (group1) (Crcl ≥90ml/min) 
(n=219), stage2 (Crcl 60-89ml/min) (group 2) (n=181), stage3, 
(group 3) (Crcl 30-59ml/min) (n=64) and stage4 (group 4) (Crcl 
<30ml/min) (n=38).
Demographic, anthropometric and hemodynamic de-tails like 
age, gender, systolic blood pressure (SBP), di-astolic blood pres-
sure (DBP), family history and dura-tion of  diabetes were re-
corded. BMI was calculated. Biochemical details like fasting and 
postprandial plasma glucose, HbA1c, lipid profile, urea, creatinine 
and 24hr proteinuria values were recorded. All the biochemical 
estimations were done by using standard enzymatic procedures 
using Hitachi auto analyzer 912. Plasma glucose was estimated 
by glucose oxidase peroxidase method. HbA1c was measured by 
HPLC (Bio-Rad) method. Renal parameters like urea were esti-
mated by kinetic enzymatic UV assay. Serum or urine creatinine 
was estimated by Jaffe’s kinetic method. Urinary pro-tein was 
determined by turbidimetric procedure using trichloroacetic acid 
reagent. Fasting serum samples were used to estimate total cho-
lesterol by using spe-cific enzymatic reagents which react with 
cholesterol oxidase-PAP. Triglyceride by GPO-PAP method, low 
density lipoprotein cholesterol by direct method and high density 
lipoprotein cholesterol enzymatically by cholesterol esterase and 
cholesterol oxidase coupled with polyethylene glycol to the amino 
groups. Very low density lipoprotein cholesterol was calculated by 
divid-ing triglyceride by 5 (TG/5).
Presence of  other diabetic complications like diabetic neuropa-
thy, peripheral vascular disease and coronary artery disease (CAD) 
occurred during the follow-up visits was noted. Neuropathy was 
diagnosed as Vibra-tion Perception Threshold >25V by bioth-
esiometer [14]. Peripheral vascular disease was diagnosed if  the 
ankle brachial index was <0.8. The presence of  CAD was defined 
by any history of  CAD, hospital records of  confirmed myocardial 
infarction and definite histo-ry of  angina or coronary revascu-
larization procedure. Out of  502 subjects, 272 subjects who had 
follow-up details were again divided as per KDOQI guidelines 
and DR status. Outcome of  the subjects was deter-mined from 
their current status of  DR and DN com-pared to their baseline 
status. Subjects who died were recorded and the cause of  death 
was obtained and not-ed from the hospital mortality register. Car-
diovascular death was defined as death caused by ischaemic heart 
disease, definite history of  angina, stroke or sudden death.
 
During follow-up visits, subjects were coded as im-proved if  they 
showed improvement in their renal sta-tus as per KDOQI stages 
and decrease in the severity of  their retinopathy status. Subjects 
were considered as retaining same status if  during their follow-up 
they were found to be in the same stage of  renal and DR status; 
however they were considered as deteriorated if  they showed de-
terioration in DR and DN status com-pared to baseline status. 
Latest status available for the subjects who died was noted.
Statistical Methods
The analysis was performed using SPSS (version 16.0, Illinois, 
USA) software. Mean and SD and proportions are reported as 
relevant. Unpaired student’s t-test was used to compare continu-
ous variables and chisquare test was used to evaluate proportions 
between groups.
Cox’s proportional hazard model (Forward stepwise addition 
method) was used to examine the predictive factors for the occur-
rence of  the two complications. The model included age, gender, 
BMI, hypertension, family history of  diabetes, duration of  diabe-
tes, smok-ing habit, HbA1c and presence of  other complications 
like diabetic neuropathy and cardiovascular disease, to-tal choles-
terol, triglycerides and Crcl as independent variables. All the sub-
jects having the follow-up data and showing decline in any of  the 
two complications were included as dependent variable. Subjects 
who at-tained mortality were excluded from the analysis.
Kaplan Meier survival analysis was performed for 253 subjects 
who had follow-up details available to deter-mine their survival 
time.
Results
A total of  502 subjects at baseline were categorized according to 
their DR and Crcl status. Table 1 summa-rizes the baseline demo-
graphic, hemodynamic, anthro-pometric and biochemical details 
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of  the study groups as per grades of  DR. There was no signifi-
cant differ-ence observed in age, BMI, family history and duration 
of  diabetes, presence of  hypertension and smoking habit among 
the groups. SBP was significantly higher in subjects with PDR. 
HbA1c% was similar among the groups. Subjects with PDR had 
significantly higher urea levels than subjects with NPDR. The 
mean Crcl values decreased significantly with increasing severity 
of  DR (p<0.001).
Table 2 shows baseline demographic, anthropomet-ric, haemo-
dynamic, biochemical and DR status of  the groups as per stages 
of  Crcl. Age, BMI, presence of  positive family history and dura-
tion of  diabetes, smok-ing habit were similar among the groups. 
Presence of  hypertension was significantly higher among group3 
and group4 (p=0.001). Blood pressure values were sig-nificantly 
higher among group4 than groups 1 and 2. There was no sig-
nificant difference noted among the four groups with respect to 
their glucose levels. Urea and creatinine levels were higher among 
groups 3 and 4. At baseline, among group1, NPDR was found in 
102 (44.2%), 102 (44.2%) subjects had NPDR with Maculopa-
thy and 15 (37.5%) had PDR. Similarly, in group2, 90 (39%) had 
NPDR, 79 (34.2%) had NPDR with maculopathy and 12 (30%) 
had PDR. In Group3, it was 22 (9.5%), 33 (14.3%) and 9 (22.5%) 
respectively whereas it was 17 (7.4%), 17 (7.4%) and 4 (10%) of  
subjects in group 4. The percentage of  subjects with NPDR de-
creased drastically with decreasing Crcl.
Table 3 shows the comparison of  baseline and follow-up details, 
retinopathy status and mortality as per stages of  Crcl in a sub-
group of  272 subjects who had follow-up details out of  502 sub-
jects. There was no significant difference in age, BMI and SBP in 
the baseline and follow-up data. DBP was higher in group4 with 
Crcl<30ml/min compared to groups 1 and 2 at baseline whereas 
DBP values were similar at follow-up. There was no statistically 
significant difference noted in lipid profile both in the baseline 
and follow-up data except triglycerides at follow-up.
At follow-up, in group1, 12.5% had no DR, 38.8% had NPDR, 
31.3% had NPDR and Maculopathy, and 17.5% had PDR. In 
group2, the percentage of  subjects with no NPDR was 4.3%, 
31.4% had NPDR, 50% had NPDR and Maculopathy, 14.3% of  
subjects had PDR. Similarly, in group3, the percentages were 3.7 
vs 31.5 vs 44.5 vs 20.4% respectively. None of  the sub-jects were 
without retinopathy in group4, while 18.4% had NPDR, 55.1% 
had NPDR with Maculopathy and 26.5% had PDR. Table 3 also 
shows the number of  cases died during follow-up.
In the baseline data, group 1 subjects with Crcl ≥90 ml/min, 
15.2% of  subjects were treated with ACE in-hibitors (ACEI), 
7.1% with Angiotensin II Receptor Blocker antagonist (ARB), 
27.7% with combination of  ACEI and ARB, 2.7% with beta 
blockers (BB) and 47.3% of  subjects were treated with a combi-
nation of  any two or three drugs. In Group 2 subjects with Crcl 
60-89 ml/min, about 3.5% were treated with ACEI, 21.2% with 
ARB, 7% with a combination of  ACEI and ARB, 11.8% with 
BB and 56.5% with combina-tion of  any two or three drugs. In 
Group 3 subjects (Crcl of  30-59 ml/min), none of  them were 
treated with ACEI or BB, whereas 7.1% were treated with ARB 
and 92.8% were treated with a combination of  drugs. In Group 4 
(Crcl <30 ml/min), none of  the subjects were treated with ACEI 
or BB, 14.3% were treated with ARB and 85.7% with a combina-
tion of  drugs. At follow-up, it was 10.1 vs 8.9 vs 20.2 vs 7.9 vs 
52.8% respectively in Group 1. In Group 2, 3.0% were treated 
with ACEI, 7.6% with ARB, 25.8% with ACEI plus ARB, none 
of  them were treated with BB and
 
63.6% with a combination of  drugs. In Group 3, none of  them 
were treated with ACEI and BB, 25% were treated with ARB, 
8.3% were treated with a combina-tion of  ACEI and ARB and 
66.7% with a combination of  any two or three drugs. In group 
4, none of  them were treated with BB, 5% with ACEI, 20% with 
ARB, 10% with ACEI and ARB and 65% were treated with a 
combination of  drugs.
Table 1: Baseline demographic, anthropometric, hemodynamic and biochemical details of  the study groups as per grades 
of  diabetic retinopathy Dur-DM; duration of  diabetes, FH-DM; family history of  diabetes, HTN; Hypertension
Variables
Group 1 NPDR
n = 231
Group 2
NPDR + Maculopathy n = 231
Group 3 PDR
n = 40 P value
M:F 154:77 172:59:00 25:15:00
Values are mean ± SD
Age (years) 56 ± 7.7 56.2 ± 7.8 56.5 ± 8.1 0.945
Dur-DM (years) 12.8 ± 6 13.4 ± 6.1 14.5 ± 6.7 0.233
BMI (kg/m2) 26.8 ± 4.7 26.1 ± 4.5 26.1 ± 4.1 0.239
Blood Pressure (mmHg)
Systolic
Diastolic
136.6 ± 16.3
82.6 ±7.6
139.8 ± 18.6
84.5 ± 9.1
143.1 ± 21.4*
83.5 ± 11.9
0.038
0.073
HbA1c (%) 9.5 ± 1.8 9.6 ± 1.9 9.9 ± 2.6 0.431
Urea (mmol/L) 5.7 ± 3.2 5.8 ± 3.2 7.5 ± 5.7*,# 0.008
Creatinine (μmol/L) 97.2 ± 79.5 106.0 ± 70.7 132.6 ± 123.7 0.105
Creatinine clearance (ml/
min) 87.1 ± 32.6 78.8 ± 30.8* 66.7 ± 30.2*
<0.0001
Values are n (%)
FH- DM 144 (62.3) 154 (66.7) 27 (67.5) 0.579
Presence of  HTN 172 (74.5) 177 (76.6) 30 (75) 0.861
Smoking 30 (13) 34 (14.7) 5 (12.5) 0.84
                 p<0.05; * Vs NPDR; # Vs NPDR+Maculopathy
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Table 2: Clinical characteristics of  the study groups as per stages of  Creatinine clearance (Crcl)
Dur-DM; Duration of  diabetes, FH-DM; family history of  diabetes
Variables
Group 1 Crcl 
≥90ml/min n = 
219
Group 2 Crcl 60-
89ml/min n = 181
Group 3 Crcl 30- 
9ml/min = 64
Group 4 Crcl 
<30ml/min n = 
38
P Value
M:F 158:61 113:68 51:13:00 29:09:00 --
Values are mean ± SD
Age (years) 55.5 ± 7.9 56.9 ± 7.5 56.6 ± 6.8 55.5 ± 9.3 0.24
Dur-DM (Years) 12.9 ± 6.3 13.8 ± 5.9 13.9 ± 5.7 13.8 ± 6.7 0.246
BMI (Kg/m2) 26.6 ± 4.2 26.7 ± 4.9 25.3 ± 4.7 25.4 ± 3.6 0.066
Blood Pressure 
(mmHg)
Systolic
Diastolic
137.6 ± 17.8
83.2 ± 8.6
137.5 ± 16.8
82.6 ± 7.9
143.1 ± 17.2
84.4 ± 17.2
146.1 ± 22.2*,**
88.8 ± 11.1*,**
0.021
0.001
Plasma Glucose 
(mmol/L)
Fasting
Post prandial
9.6 ± 4.2
13.6 ± 4.7
10.1 ± 4.1
13.6 ± 4.9
10.4 ± 5.8
13.1 ± 4.9
8.2 ± 3.6
11.5 ± 3.4
0.102
0.067
Urea (mmol/L) 4.8 ± 2.7 5.3 ± 1.9 7.5 ± 2.9*,** 12.4 ± 6.6*,**,# <0.0001
Creatinine 
(μmol/L)
79.6 ± 44.2 88.4 ± 26.5 141.4 ± 61.9*,** 282.9 ± 168.0*,**,# <0.0001
Values are n (%)
FH- DM 151 (68.9) 110 (60.8) 40 (62.5) 24 (63.2) 0.372
Presence of  HTN 148 (67.6) 142 (78.5) 56 (87.5) 33 (86.8) 0.001
Smoking 32 (14.6) 23 (12.7) 8 (12.5) 6 (15.8) 0.915
DR status
NPDR
102 (44.2) 90 (39) 22 (9.5) 17 (7.4) <0.0001
NPDR + Macu-
lopathy
102 (44.2) 79 (34.2) 33 (14.3) 17 (7.4) <0.0001
PDR 15 (37.5) 12 (30) 9 (22.5) 4 (10) 0.041
       * Vs Crcl ≥90ml/min; ** Vs Crcl 60-89ml/min; # Vs Crcl 30-59ml/min
Table 3: Comparison of  biochemical details and retinopathy status at baseline and during follow-up in a subgroup of  sub-
jects as per stages of  Creatinine clearance
Baseline details (n = 272) Follow-up Details (n = 253)
Variables Group 
1 Crcl 
≥90ml/ 
min n = 
126
Group 2 
Crcl 60- 
89ml/min 
n = 88
Group 
3 Crcl 
30-59ml/ 
min n 
= 35
Group 4 Crcl 
<30ml/ min 
n = 23
P 
Value
Group 
1 Crcl 
≥90ml/ 
min n = 80
Group 2 
Crcl 60- 
89ml/min 
n = 70
Group 3 
Crcl 30- 
59ml/min 
n = 54
Group 
4 Crcl 
<30ml/ 
min n = 49
P 
Value
Values are mean ± SD
Age (years) 55.6 ± 8.3 57.1 ± 7.4 57.9 ± 7.3 55.4 ± 8 0.282 58±8.2 58.9±7 59.3±8 59.3±7.6 0.05
BMI (kg/m2) 26.6 ± 4.3 27.6 ± 5.2 25.8 ± 4.6 25.6 ± 3.3 0.115 28.4±4.8 28.1±3.9 27.2±4.9 26.5±4.2 0.119
Blood Pressure
(mmHg)
Systolic
Diastolic
137.3±15.9
82.5±8.6
137.6±17.6
82.4±8.2
140.6±18
84.9±8.2
146.7±20.3
88.9±10.4*,**
0.09
0.005
137.2±16.9
82.2±5.9
137.6±17
83.1±7.5
136.6±16.4
83.4±6.7
144.9±21.2
83.7±9.5
0.073
0.71
Plasma Glu-
cose (mmol/L)
Fasting
Post Prandial
9.7±4.1
13.6± 4.9
10.1±3.9
13.2±4.7
9.7±5.3
12.6±4.6
7.7±2.9
10.4±2.8*
0.092
0.02
8.9±3.3
13.4±3.7
8.7±3.4
12.9±4.4
8.6±3.1
13.1±3.7
7.7±3.5
11.9±3.8
0.351
0.267
T-Chol
(mmol/L)
4.8±1.3 4.83±1.33 4.87±1.4 4.76±1.45 0.968 4.3±1.19 4.4±1.4 4.39±1.48 4.29±1.5 0.989
Triglycerides
(mmol/L)
1.9±0.91 2.1±1.1 2.18±1.1 2.07±1.0 0.374 1.73±0.87 1.67±0.75 2.3±1.1** 1.9±1.0 0.024
HDL
(mmol/L)
1.14±0.32 1.1± 0.29 1.13±0.22 1.22±0.36 0.278 1.1±0.28 1.08±0.26 1.06±0.35 0.99±0.23 0.565
LDL (mmol/L) 2.87±0.96 2.86±1.08 2.89±1.18 2.67±1.1 0.852 2.57±0.92 2.68±0.97 2.56±1.03 2.53±1.16 0.903
VLDL
(mmol/L)
0.7±0.43 0.89±0.46 0.86±0.5 0.87±0.48 0.119 0.69±0.43 0.66±0.43 0.86±0.45 0.76±0.46 0.229
Crcl (ml/min) 109.3±18.8 74.4±9.5* 43.7±8.5*
,**
19.3±6.8*,
**,#
<0.001 102.6±20.7 79.5±15.9* 51.5±12.9*
,**
23±17.3*,
**,#
<0.001
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Table 4 shows the conversion of  272 subjects from baseline till 
median follow-up of  22 months as per Crcl and DR stages. Con-
sidering Crcl stages, among group1, none of  the subjects showed 
improvement in renal status, 40.5% remained similar as baseline, 
54.8% showed deteriorated renal status from baseline. Among 
group2, 31.8% improved, 14.8% remained same and 51.1% had 
deteriorated renal status. In group3, im-provement was seen in 
17.1%, 8.6% remained same and 62.9% had worsened renal sta-
tus. In group4, 13% showed improvement, 56.5% remained same 
and none of  them showed deterioration in the renal status. The 
percentages of  subjects who died were 4.8, 2.3, 11.4 and 30.4 % 
in the four groups respectively (Table 4, Panel A).
Conversion of  study subjects from baseline till medi-an follow-up 
of  22 months as per DR stages showed that among NPDR group, 
14.5% had improved retinal status, 21.4% remained same as base-
Values are n (%)
No DR No DR No DR No DR No DR No 
DR
No DR No DR No DR No DR
NPDR NPDR NPDR NPDR NPDR NPDR NPDR NPDR NPDR NPDR
NPDR +
Maculopathy
NPDR +
Maculopa-
thy
NPDR +
Maculopa-
thy
NPDR +
Macu-
lopa-
thy
NPDR +
Maculopa-
thy
NPDR
+ 
Macu-
lopa-
thy
NPDR +
Maculopa-
thy
NPDR +
Maculopa-
thy
NPDR +
Maculopa-
thy
NPDR +
Maculopa-
thy
PDR PDR PDR PDR PDR PDR PDR PDR PDR PDR
Mortality Mortality Mortality Mortality Mortality Mor-
tal-
ity
Mortality Mortality Mortality Mortality
          * Vs Crcl ≥90ml/min; ** Vs Crcl 60-89ml/min; # Vs Crcl 30-59ml/min
Table 4 Panel A: Conversion of  the study subjects from baseline till median follow-up of  22 months as per Creatinine clear-
ance stages
Crcl stages Improved Same 
Status
Deterio-
rated
Mortality
Groups Baseline/ Follow-up n 37 80 136 19
Group 1 Crcl ≥90ml/min 126 -- 51 (40.5) 69 (54.8) 6 (4.8)
Group 2 Crcl 60-89ml/min 88 28 (31.8) 13 (14.8) 45 (51.1) 2 (2.3)
Group 3 Crcl 30-59ml/min 35 6 (17.1) 3 (8.6) 22 (62.8) 4 (11.4)
Group 4 Crcl <30ml/min 23 3 (13.04) 13 (56.5) -- 7 (30.4)
                       Values are n (%)
Table 4 Panel B: Conversion of  the study subjects from baseline till median follow-up of  22 months as per Diabetic Retin-
opathy (DR) stages
DR stages Improved Same Status Deteriorated Mortality
Baseline/ Follow-up N 55 93 105 19
NPDR 131 19(14.5) 28(21.4) 77 (58.8) 7 (5.3)
NPDR + Maculopathy 119 29 (24.4) 51 (42.8) 28 (23.5) 11 (9.2)
PDR 22 7 (31.8) 14 (63.6) -- 1 (4.5)
                       Values are n (%)
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Figure 1. shows the Kaplan Meier survival analysis of  the individuals who had follow up details
Survival Function at mean of  covariates
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line, 58.8% had deteriorated retinal status and 5.3% of  subjects 
died.
Among NPDR with maculopathy, 24.4% improved, 42.8% re-
mained same, 23.5% had deteriorated retinal status and the 
percentage of  subjects who died was 9.2%. In PDR, 31.8% im-
proved, 63.6% remained same, none of  the subjects deteriorated 
while 4.5% died (Table 4, Panel B). The cause of  death was either 
due to renal failure or cardiovascular events.
As per the Cox’s proportional hazard model, consider-ing all 
the subjects who had follow-up data and had showed deterio-
ration in any of  the two complications over a median follow-
up of  22 months as dependent variable, total cholesterol with 
Hazard Ratio (HR) of  1.004, 95% confidence interval (CI) 
(1.001-1.007),(P=0.007) and Crcl with HR of  0.995, 95% CI 
(0.990-1.000), (P=0.041) emerged as significant determinants of  
declining status in the subjects having both the complications as 
compared to baseline. Subjects who died were not included in this 
analysis.
Figure 1 shows the survival rate of  subjects with both compli-
cations with respect to duration of  follow-up in months. It was 
observed that there is a continuous decline in the survival rate 
once both the complica-tions are attained. Nearly, 60% deterio-
rated at about 22 months. It was also found that the survival will 
be for a maximum of  68 months with the presence of  both the 
complications.
Discussion
It is a well known fact that subjects with diabetes are at high risk 
of  developing complications such as nephropathy, retinopathy 
and neuropathy than subjects without diabetes [15]. DR is char-
acterized by micro-vascular abnormalities, proliferation of  reti-
nal vessels and increased retinal vascular permeability leading to 
the development of  non proliferative and proliferative DR and 
macular edema [16]. DN is a life threatening complication which 
predisposes to excess morbidity and mortality resulting from re-
nal failure and cardio-vascular disease[17,18]. Our hypothesis was 
that to see whether the severity of  DR had any relationship with 
the presence and severity of  DN in people with type2 diabetes. 
Studies in other populations documented a well known associa-
tion between advanced DR stages and macroalbuminuria in type2 
diabetic patients [19,20]. Data from developing countries show-
ing the rela-tionship between these two diabetic complications are 
sparse but the current study supports the close rela-tionship be-
tween presence of  DR and severity of  DN among type 2 diabetic 
patients in India.
It was reported that atleast one fifth of  the diabetic individuals are 
affected by multiple complications and the frequency increases 
with increasing age and dura-tion of  diabetes [21]. Our study sub-
jects were also old-er and had longer duration of  diabetes which 
evidently proved that increased age and duration of  diabetes were 
responsible for the development of  both the complications. In 
the baseline data, the groups were matched with respect to age, 
BMI, presence of  posi-tive family history of  diabetes, glucose lev-
els, smoking habit and duration of  diabetes both as per grades of  
DR and stages of  Crcl.
A study from Jordan showed that nephropathy, which is assumed 
to result from other microvascular compli-cations of  diabetes, 
was found to be significantly as-sociated with DR [22]. In WES-
DR, there was a strong correlation between DN and severity of  
DR in all age groups [23,24]. Our study results also complied with 
similar findings of  worsening of  DN with increasing severity of  
DR. In our study, the mean Crcl was found to be decreased sig-
nificantly with increasing severity of  DR. The percentage of  sub-
jects with NPDR also de-creased with decreasing Crcl.
In contrast to the well known 3 major risk factors for the de-
velopment of  microvascular disease, such as gly-cemic status, 
hypertension and duration of  diabetes, our study revealed total 
cholesterol and Crcl to be sig-nificantly associated with the declin-
ing status of  both the complications by Cox’s proportional hazard 
model. When comparing basal and follow-up mean lipid lev-els, 
there was no significant difference noted except triglycerides at 
follow-up, but total cholesterol showed significant association in 
this analysis.
Findings from our study also highlighted that the mor-tality rate 
will be high when both DR and DN co-occur. Continuous de-
cline of  renal function was also found to be correlating with the 
advanced stages of  DR. In the follow-up data, severity of  DR 
increased compared to baseline as per stages of  Crcl. More num-
ber of  sub-jects died who had Crcl <30 ml/min at follow-up. The 
cause of  death was either renal failure or cardiovas-cular event. 
Similar to our findings Trevisan et.al also revealed that there was a 
drastic reduction in kidney function and higher death rate among 
type 2 diabetes in the presence of  both the complications [25].
Since the mortality rate of  the patients in our study was high, it 
was also observed that once both the com-plications occur, the 
improvement was seen in much lesser percentage of  subjects in a 
median follow-up pe-riod of  22 months. Approximately 60% of  
subjects re-mained in the same status of  severe Crcl or DR stages. 
Majority of  the patients remained in the same status as that of  
baseline. This could be because the follow-up period considered 
is too short to observe probable changes. This is one of  the limi-
tations of  our study. A decline in survival was noted when both 
the com-plications are present and about 60% of  the cases de-
teriorated at about a median follow-up of  22 months. The maxi-
mum survival rate was less than 65 months. A similar declining 
pattern was observed in another study stating only 22.2% survival 
rate in 10 years follow-up of  type 1 diabetic patients [26].
 
Another limitation was that it was not a prospectively planned 
randomized study. The analysis was done with the available hospi-
tal based data, so the effect of  other potential confounders needs 
to be studied in future. There was a lack of  systematic examina-
tion of  both the complications during follow-up. The data was 
col-lected retrospectively and survival analysis was done only for 
the subjects whose follow-up details were available. However, ut-
most care has been taken while collecting the data of  subjects 
who had follow-up of  both the complications.
The present study highlights the need for screening the patients 
periodically to look for diabetic compli-cations. Modification of  
risk factors with appropriate treatment strategies may delay the 
progression of  these diabetic complications. In conclusion, a pos-
itive asso-ciation was found between the degree of  DR and DN 
in type2 diabetes. Patients with DR should undergo an evaluation 
of  renal function and vice-versa.
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